Nivolumab (Opdivo®) is an immunotherapy drug that is already approved for the treatment of advanced kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
Nivolumab is often combined with another drug called Ipilimumab (Yervoy®). This is another type of immunotherapy which targets a molecule called CTLA-4 and allows the body to increase the number of immune cells available to attack and destroy cancer cells.
Under the right circumstances, these drugs have been shown to be more effective when taken together than when taken separately.
This study will investigate whether the combination of Nivolumab and Ipilimumab can be used in patients a second time, even after they have already stopped responding to the treatment at an earlier time point.
This is a single-group study, so there is no randomization, no placebo, and all patients will receive treatment.
- All subtypes eligible
- Patient must have received and subsequently stopped responding to Ipilimumab/Nivolumab treatment
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer Agency - Vancouver Centre||Principal InvestigatorDr. Christian Kollmannsberger||LocationVancouver, BC||Trial StatusRecruiting|
|Hospital / Cancer CentreTom Baker Cancer Centre||Principal InvestigatorDr. Daniel Heng||LocationCalgary, AB||Trial StatusPending|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorDr. Naveen Basappa||LocationEdmonton, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorDr. Sébastien Hotte||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSunnybrook Health Sciences Centre||Principal InvestigatorDr. Georg Bjarnason||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorDr. Aaron Hansen||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreCentre hospitalier de l'Université de Montréal - CHUM||Principal InvestigatorDr. Denis Soulières||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreJewish General Hospital||Principal InvestigatorDr. Wilson Miller||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreHôtel-Dieu de Québec||Principal InvestigatorDr. Vincent Castonguay||LocationQuebec City, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreCIUSSS de l'Estrie - CHUS||Principal InvestigatorDr. Michel Pavic||LocationSherbrooke, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreQEII Health Sciences Centre||Principal InvestigatorDr. Lori Wood||LocationHalifax, NS||Trial StatusRecruiting|